WO2003104247A2 - Cdg-therapie mit mannose - Google Patents
Cdg-therapie mit mannose Download PDFInfo
- Publication number
- WO2003104247A2 WO2003104247A2 PCT/EP2003/005986 EP0305986W WO03104247A2 WO 2003104247 A2 WO2003104247 A2 WO 2003104247A2 EP 0305986 W EP0305986 W EP 0305986W WO 03104247 A2 WO03104247 A2 WO 03104247A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mannose
- alkyl
- nmr
- phosphate
- radicals
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
- C07H11/04—Phosphates; Phosphites; Polyphosphates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
- C07H13/06—Fatty acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
Definitions
- the invention relates to mannose 1-phosphate derivatives, pharmaceutical and dietetic agents containing them and the use of these derivatives for the treatment of congenital glycosylation disorders.
- CDG Congenital Disorders of Glycosylation
- the CDG-la is one of the most common congenital glycosylation disorders and was first described phenotypically in 1980, see Jaeken, J .; Vanderschueren-Lodeweyckx, M .; Casaer, P .; Snoeck, _ .; Corbeel, L .; Eggermont, Ex, Edckels, R. Pediatr. Res. 1980, 14, 179.
- This disease is based on a defect in phosphomannomutase 2, a cytoplasmic enzyme that catalyzes the conversion of mannose 6-phosphate to mannose 1 -phosphate.
- the mannose 1 phosphate is the starting substance for the Production of GDP-mannose.
- This sugar nucleotide is required to incorporate mannose into dolichol-linked oligosaccharide chains, which are then used for the N-glycosylation of proteins.
- An alternative biosynthetic pathway does not exist. In the absence of a corresponding transporter in the cell membrane, the substance is not taken up by the extracellular space. Although the hypoglycosilation of glycoproteins in fibroblasts can be reduced by adding mannose to the culture medium, all attempts to successfully treat CDG-la children have so far failed, E. Mayatepek et al. in Eur.J. Pediatr. 157: 605-606 and in I. Acta Pediatr. 86: 1 138-1140.
- the object of the present invention is to show a way of treating congenital glycosylation disorders and in particular CDG-la.
- mannose 1 phosphate derivatives provided according to the invention are compounds which are hydrophobically masked. Without being bound by this explanation, it is believed that hydrophobically masked mannose 1-phosphate derivatives are able to cross the hydrophobic cell membrane. Once in the cytoplasm, the compounds can be cleaved by cytoplasmic enzymes, so that mannose 1-phosphate is released. This compensates for the intracytoplasmic deficiency of mannose 1-phosphate mentioned at the beginning.
- the invention thus relates to mannose 1 phosphate derivatives of the following general formula I.
- R and R 2 which may be the same or different, for
- R 3 and R 4 which may be the same or different, for
- radical R 3 can also be H, where
- Aryl means an aromatic hydrocarbon radical which may be substituted by an alkyl radical and
- Alkyl a linear or branched, saturated
- Hydrocarbon radical having 1 to 20 carbon atoms.
- radicals R1 and R2 can have the following meanings, for example: OOO
- R 1 and R 2 together can represent, for example, the following radicals.
- n stands for 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1, 12, 13, 14, 15, 16, 17, 18 and 20.
- radicals R 3 and R 4 which may be the same or different, are, for example
- R 1 and R 2 are preferably the same. Furthermore, all R 3 radicals are preferably the same. Not all are further preferred R 3 radicals as such are the same, but also the R 4 radical is the same as the R 3 radicals.
- the alkyl radical or the alkyl group in one or more of the radicals R 1 , R 2 , R 3 and R 4 is CH 3 -C (CH 3 ) 3, -CH (CH 3 ) 2 and - CH 2 -CH 2 -CH 3 .
- the aryl radical can be, for example, a phenyl or naphthyl radical, this radical being substituted by one, two, three or even more alkyl radicals as defined above.
- the mannose 1-phosphate derivatives according to the invention can be prepared by the synthetic route shown in FIG. 1.
- benzylmannopyranoside is obtained by Fischer glycosylation with benzyl alcohol ⁇ Dziewiszek, K .; Banaszek, A .; Zamojski, A. Tetrahedron Lett. 1987, 28, 1569).
- This compound is converted into the appropriately substituted mannopyranosides, butyryl chloride, pivaloyl chloride or isopropyl chloroformate being used (Ogilvie, KK; Letsinger, RLJ Org. Chem. 1967, 32, 2365; Nicolaou, K. C; Webber, SE Synthesis 1986, 453).
- Subsequent hydrogenolysis of the benzyl groups on Pd / C (10%) gives the anomerically unblocked mannose derivatives 1-3.
- the phosphates 7-9 obtained are converted into their acetoxymethyl (AM) and pivaloyloxymethyl (POM) esters 10-15, bromomethyl acetate or iodomethyl pivaloate being used in the presence of N-ethyl-di-iso-propylamine (DIPEA).
- AM acetoxymethyl
- POM pivaloyloxymethyl
- DIPEA N-ethyl-di-iso-propylamine
- the invention also relates to pharmaceutical and dietetic agents which contain at least one mannose according to the invention as active substance.
- 1-phosphate derivative included There can thus be 1, 2, 3, 4 such derivatives.
- the agent according to the invention can consist exclusively of a mannose-1-phosphate derivative according to the invention. In this case there are no auxiliary substances, carriers, adjuvants etc. However, the latter can also be present in an agent according to the invention, be it a pharmaceutical or a dietetic agent. Furthermore, one or more other active ingredients can be incorporated into the agent according to the invention.
- the agents according to the invention can be produced in a simple manner, for example by mixing, mixing etc. and can be administered in a suitable form, for example as a powder, as a tablet, as a capsule and in any other suitable galenic form.
- the agent according to the invention can also be a dietary agent.
- the mannose-I-phosphate derivatives according to the invention are added, for example, to a food or a dietary product. This can also be done, for example, as part of a diet.
- the agents according to the invention are used for the treatment of congenital glycosylation disorders and in particular for the treatment of CDG-Ia patients.
- the agents according to the invention can also be used when it is necessary to “lock” hydrophobically masked mannose derivatives through hydrophobic cell membranes.
- the subject is therefore also the use of mannose-1-phosphate derivatives of the general formula I, in which the radicals R 1 , R 2 , R 3 and R 4 form physiologically occurring carboxylic acid groups which, via the OH group of the mannose base body, in Form of esters are bound to it, where R 3 can also denote a hydrogen atom, for the treatment of congenital glycosylation disorders or for the preparation of agents for the treatment of such congenital glycosylation disorders.
- carboxylic acid groups are preferably short and physiologically occurring carboxylic acids.
- Mannose-1-phosphate derivatives of the general formula I are preferably used, in which the radicals R 1 , R 2 , R 3 and R 4 have the possible meanings specifically disclosed in the present documents and in the patent claims.
- mannose-1-phosphate derivatives according to the invention are used in particular for the treatment of CDG-la.
- Figure 1 is a synthesis scheme in a formula for
- FIG. 2 structural formulas of individual mannose-1 according to the invention
- Phosphate derivatives the specific preparation of some of these derivatives is described in more detail in the examples below.
- the preparation of the mannose-1-phosphate derivatives according to the invention is explained below on the basis of preferred species.
- the NMR spectra were recorded with Bruker AC-250, AMX-400 and DRX-500. The chemical shifts for 1 H NMR and 13 C NMR are given with respect to tetramethylsilane. 85% phosphoric acid was used as an external standard for 31 P NMR. Optical rotation was determined using a Perkin-Elmer 341 polarimeter. The melting points were measured with ST-Apotec and are not corrected.
- MALDI-TOF spectra were recorded on Bruker Biflex III and ESI spectra on aHP Series 1100 MSD.
- Pre-coated plates were used for thin layer chromatography (TLC), silica gel 60 GF 254 (Merck). The detection was carried out by observation under UV light at 254 nm and by spraying with 10% strength ethanolic sulfuric acid and then heating. Column chromatography was performed using the flash technique using silica gel 60 (230-400 mesh, 0.040-0.063 mm, Merck).
- Iodomethyl pivaloate was synthesized in a known manner.
- Benzylmannopyranoside was dissolved in dry pyridine (0.1M solution) at 0 ° C. Butyryl chloride (3 eq / OH), pivaloyl chloride (3 eq / OH) or isopropyl chloroformate (1, 5 eq / OH, 1 M toluene) were added dropwise. The mixture was stirred at room temperature overnight.
- Compound 1 was prepared in the manner described above.
- Mannopyranosyl-1-phosphate 7 (111 mg, 0.21 mmol) was suspended in dry acetonitrile (1 ml). DIPEA (0.11 ml, 0.62 mmol) and iodomethyl pivaloate (0.15 g, 0.62 mmol) were added. The mixture was stirred at room temperature overnight; then the solvent was removed and the residue dissolved in ethyl acetate. The mixture was grown twice with saturated saline, dried over sodium sulfate, filtered and concentrated under reduced pressure. The product was purified by column chromatography (petroleum ether / ethyl acetate + 1% Et 3 N, 1: 1), the compound 11 being obtained in a 24% yield (39 mg, 0.05 mmol, syrup).
- Mannopyranosyl-1-phosphate 8 (269 mg, 0.45 mmol) was suspended in dry acetonitrile (3 ml) and dry toluene (0.5 ml). DIPEA (0.22 ml, 1.35 mmol) and bromomethyl acetate (0.13 ml, 1.35 mmol) were added. The mixture was stirred at room temperature overnight, the reaction being monitored by TLC (petroleum ether / ethyl acetate, 1: 1). After further addition of bromomethyl acetate (0.1 ml, 1.02 mmol) and DIPEA (0.1 ml, 0.59 mmol), the suspension was stirred again at room temperature for 2 days.
- Mannopyranosyl-1-phosphate 9 (25.6 mg, 0.04 mmol) was prepared in the same way [dry acetonitrile (1 ml + 1 ml + 0.5 ml), DIPEA (0.02 ml, 0.12 mmol + 0.04 ml, 0.24 mmol), bromomethyl acetate (96 ⁇ l, 0.98 mmol), stirred for 3 days, column chromatographically treated with petroleum ether / ethyl acetate (1: 1)] as in the case of compound 10.
- Compound 14 (5.4 mg, 7.2 ⁇ mol) was obtained as a colorless syrup in a yield of 17%.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE50302198T DE50302198D1 (de) | 2002-06-07 | 2003-06-06 | Cdg-therapie mit mannose |
EP03757039A EP1521761B1 (de) | 2002-06-07 | 2003-06-06 | Cdg-therapie mit mannose |
AU2003246402A AU2003246402A1 (en) | 2002-06-07 | 2003-06-06 | Treatment of congenital disorders of glycosylation (cdg) using mannose |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10225628A DE10225628A1 (de) | 2002-06-07 | 2002-06-07 | CDG-Therapie mit Mannose |
DE10225628.4 | 2002-06-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003104247A2 true WO2003104247A2 (de) | 2003-12-18 |
WO2003104247A3 WO2003104247A3 (de) | 2004-02-12 |
Family
ID=29594345
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2003/005986 WO2003104247A2 (de) | 2002-06-07 | 2003-06-06 | Cdg-therapie mit mannose |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1521761B1 (de) |
AT (1) | ATE315570T1 (de) |
AU (1) | AU2003246402A1 (de) |
DE (2) | DE10225628A1 (de) |
WO (1) | WO2003104247A2 (de) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007096532A1 (fr) * | 2006-02-24 | 2007-08-30 | Oe Operations | Mannosyl-1 phosphates, procede de preparation et utilisation en therapeutique, notamment vis-a-vis du syndrome cdg-ia |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160025717A1 (en) | 2013-03-14 | 2016-01-28 | Emory University | Hyposialylation disorders |
US10493087B2 (en) | 2015-02-25 | 2019-12-03 | The United States of America, as represented by National Institute of Health | Sialylation-increasing therapies for diseases associated with oxidative stress |
AU2019326265A1 (en) | 2018-08-20 | 2021-04-15 | Maggie's Pearl, Llc | Methods for treating congenital disorders of glycosylation |
-
2002
- 2002-06-07 DE DE10225628A patent/DE10225628A1/de not_active Withdrawn
-
2003
- 2003-06-06 EP EP03757039A patent/EP1521761B1/de not_active Expired - Lifetime
- 2003-06-06 WO PCT/EP2003/005986 patent/WO2003104247A2/de not_active Application Discontinuation
- 2003-06-06 AU AU2003246402A patent/AU2003246402A1/en not_active Abandoned
- 2003-06-06 DE DE50302198T patent/DE50302198D1/de not_active Expired - Lifetime
- 2003-06-06 AT AT03757039T patent/ATE315570T1/de active
Non-Patent Citations (5)
Title |
---|
GR]NEWALD, S. ET AL.: "Congenital disorders of glycosylation: a review" PEDIAT.RES., Bd. 52, Nr. 5, 2002, Seiten 618-624, XP009019434 * |
KNERR, LAURENT ET AL: "Efficient synthesis of hydrophilic phosphodiester derivatives of lipophilic alcohols via the glycosyl hydrogenphosphonate method" TETRAHEDRON LETTERS (1998), 39(3/4), 273-274, XP004100940 * |
MAYATEPEK, E. ET AL.: "Mannose supplementation in carbohydrate-deficient glycoprotein syndrome type I and phosphomannomutase deficiency" EUR. J. PEDIAT., Bd. 157, 1998, Seiten 605-606, XP002259389 in der Anmeldung erw{hnt * |
RUTSCHOW, SYNKE ET AL: "Membrane-Permeant derivatives of mannose-1-phosphate" BIOORGANIC & MEDICINAL CHEMISTRY (2002), 10(12), 4043-4049, XP002259386 * |
WARREN, C. D. ET AL.: "Chemical synthesis of dolichyl- alpha-D-mannopyranosyl phosphate and citronellyl-alpha-D-mannopyranosyl phosphate" BIOCHEM., Bd. 12, Nr. 25, 1973, Seiten 5038-5044, XP002259388 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007096532A1 (fr) * | 2006-02-24 | 2007-08-30 | Oe Operations | Mannosyl-1 phosphates, procede de preparation et utilisation en therapeutique, notamment vis-a-vis du syndrome cdg-ia |
FR2897779A1 (fr) * | 2006-02-24 | 2007-08-31 | Orphan Europ Sarl | Manossyl-1 phosphates, procede de preparation et utilisation en therapeutique, notamment vis-a-vis dy syndrome cdg-la |
Also Published As
Publication number | Publication date |
---|---|
DE10225628A1 (de) | 2003-12-24 |
WO2003104247A3 (de) | 2004-02-12 |
AU2003246402A1 (en) | 2003-12-22 |
DE50302198D1 (de) | 2006-04-06 |
EP1521761A2 (de) | 2005-04-13 |
ATE315570T1 (de) | 2006-02-15 |
EP1521761B1 (de) | 2006-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0841949B1 (de) | Verwendung von saccharid-konjugaten | |
DE3612636C2 (de) | Nucleosid-Phospholipid-Komplexe | |
EP0369182B1 (de) | Tumorhemmende Saccharid-Konjugate | |
EP0845475B1 (de) | Inositolglykane mit insulinartiger Wirkung | |
EP0098600A2 (de) | Neue D-Mannitderivate als Ausgangsprodukte zur Synthese von Phospholipiden | |
EP0354246A1 (de) | 3'-Azido-2',3'-dideoxynucleosid-5'-phosphonate | |
EP0099068B1 (de) | Neue Glycerinderivate zur Synthese von Phospholipiden | |
DE19547958B4 (de) | Anthracyclin-Derivate | |
DE2804099A1 (de) | Carminomycinderivate, verfahren zu ihrer herstellung und ihre verwendung | |
EP0338407B1 (de) | Neue Alkylphosphonoserine, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Mittel | |
EP1521761B1 (de) | Cdg-therapie mit mannose | |
DE3132221A1 (de) | Neue cyclophosphamid-derivate, verfahren zu ihrer herstellung und ihre verwendung | |
EP0300960B1 (de) | Neue pharmazeutische Präparate sowie neue Lactosylverbindungen und ihre Herstellung | |
DE69532819T2 (de) | Kohlenhydrate derivate und die enthaltende zusammensetzungen | |
CH629476A5 (de) | Verfahren zur herstellung von nitroso-harnstoff-verbindungen. | |
CH630929A5 (de) | Verfahren zur herstellung von neuen disaccaridderivaten von anthracyclinen. | |
EP0229128B1 (de) | Glycero-3(2)-phospho-l-serinderivate und diese enthaltende pharmazeutischen präparate | |
WO1994005681A1 (de) | Neue acetale von ketophosphamid und alkylglycosiden | |
DE3000246A1 (de) | Verfahren zur herstellung von l-(alpha)-glycerilphosphorycholin und das dabei erhaltene produkt | |
EP0345583A2 (de) | Neue Aldophosphamidglycoside, Verfahren zu ihrer Herstellung sowie ihre Verwendung als pharmazeutische Wirkstoffe | |
DE60117526T2 (de) | Alkylierte inositolglycane und ihre verwendung | |
EP0415198B1 (de) | Ketophosphamidglycoside, Verfahren zu ihrer Herstellung sowie ihre Verwendung als pharmazeutische Wirkstoffe | |
DE68924499T2 (de) | Verfahren zur Herstellung von Phosphatidylcholin Derivaten. | |
EP0432183B1 (de) | Neue cytidin-5'-diphosphatalkanole und- glycerole, ein verfahren zu deren herstellung, sowie deren verwendung | |
DE69826394T2 (de) | Verfahren zur herstellung von c-glykosiden der ulosonsäure |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AU BR BY CA CN HR ID IL IN JP LT LV MK NO NZ PL RU SG UA US YU ZA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003757039 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003757039 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2003757039 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |